These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. Yoo DS; Han JY; Lee KS; Choo MS Int J Clin Pract; 2012 Feb; 66(2):132-8. PubMed ID: 22188444 [TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731 [TBL] [Abstract][Full Text] [Related]
26. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Wang AC; Chih SY; Chen MC Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893 [TBL] [Abstract][Full Text] [Related]
27. Trospium chloride treatment of overactive bladder. Biastre K; Burnakis T Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592 [TBL] [Abstract][Full Text] [Related]
28. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.]. Merino Salas S Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041 [TBL] [Abstract][Full Text] [Related]
29. Transdermal oxybutynin: a new treatment for overactive bladder. Davila GW Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778 [TBL] [Abstract][Full Text] [Related]
32. The MATRIX study: evaluating the data in older adults. Newman DK Director; 2008; 16(3):15-9. PubMed ID: 19343887 [TBL] [Abstract][Full Text] [Related]
33. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. Abramov Y; Sand PK Expert Opin Pharmacother; 2004 Nov; 5(11):2351-9. PubMed ID: 15500382 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. Wang CC; Jiang YH; Kuo HC Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445 [TBL] [Abstract][Full Text] [Related]
35. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14. Cornel EB Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252 [No Abstract] [Full Text] [Related]
36. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Aaron LE; Morris TJ; Jahshan P; Reiz JL Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237 [TBL] [Abstract][Full Text] [Related]
37. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761 [TBL] [Abstract][Full Text] [Related]
39. Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. Yokoyama O; Yamaguchi A; Yoshida M; Yamanishi T; Ishizuka O; Seki N; Takahashi S; Yamaguchi O; Higo N; Minami H; Masegi Y Int J Urol; 2015 Jul; 22(7):684-8. PubMed ID: 25782032 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. Dmochowski RR; Davila GW; Zinner NR; Gittelman MC; Saltzstein DR; Lyttle S; Sanders SW; J Urol; 2002 Aug; 168(2):580-6. PubMed ID: 12131314 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]